OTCM
EKTAY
Market cap1.93bUSD
Jul 09, Last price
5.22USD
1D
2.35%
1Q
-13.54%
Jan 2017
-39.84%
Name
Elekta AB (publ)
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Elekta AB (publ) is a global medical technology company dedicated to developing and delivering advanced clinical solutions for the treatment of cancer and brain disorders. Its comprehensive portfolio includes innovative radiotherapy systems such as the Elekta Unity MR-Linac, the Elekta Harmony linear accelerator, Elekta Infinity for diverse patient radiotherapy requirements, and the Elekta Synergy digital accelerator for advanced image-guided radiation therapy. Specific solutions like Versa HD are available for managing brain metastases. The company also supplies crucial treatment management software, automated and integrated quality assurance tools, and hardware and software for motion management. Further augmenting its oncology offerings, Elekta provides MOSAIQ Plaza for integrated multidisciplinary cancer care and Elekta Axis Cloud for managed hosting. Within brachytherapy, key products include the image-guided Elekta Studio, the mobile ImagingRing CT scanner, Oncentra Brachy for streamlining repetitive tasks, the Elekta Flexitron afterloader for precise workflow execution, and specialized applicators like Venezia and Geneva for cervical cancer treatment. For neurological conditions, Elekta offers a suite of advanced radiosurgery and neurosurgery solutions. This includes the Leksell Gamma Knife series – Icon for personalized radiation treatment, Perfexion for neurosurgical applications, and Lightning for accelerated procedures. Its neurosurgery product line features the Leksell Vantage Stereotactic System for intracranial interventions and the Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. Founded in 1972, Elekta maintains its corporate headquarters in Stockholm, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑04 | 2025‑04 | 2024‑04 | 2023‑04 | 2022‑04 | 2021‑04 | 2020‑04 | 2019‑04 | 2018‑04 | 2017‑04 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||